Anticardiolipin antibodies (aCL) found in sera from patients with antiphospholipid syndrome recognize a cryptic epitope that appears on the β2-glycoprotein I (β2-GPI) molecule when β2-GPI interacts with a lipid membrane composed of negatively charged phospholipid or when β2-GPI is adsorbed on a polyoxygenated polystyrene plate. A homology based model of β2-GPI was constructed based on the NMR coordinates of sushi domains of human factor H. The conformation was like a cylinder consisting of five domains, its IV and V domains being glued by electrostatic interaction. We used phage-displayed random peptide libraries to search the epitopes of human aCL. Structures similar to consensus sequences selected by a biopanning method was found on domain IV of β2-GPI.
KoikeT. Antiphospholipid antibodies and biological false positive serological test for syphilis in patients with systemic lupus erythematosus.Clin Exp Immunol1984; 56: 193–199.
3.
McNeilHP, SimpsonRJ, ChestermanCN, KrilisSA.Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H).Proc Natl Acad Sci U.S.A.1990; 87: 4120–4124.
4.
GalliM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor.Lancet1990; 335: 1544–1547.
5.
MatsuuraE. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease.Lancet1990; 336: 177–178.
6.
MatsuuraE. Anticardiolipin antibodies recognize β2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface.J Exp Med1994; 179: 457–462.
7.
KoikeT, TsutsumiA, IchikawaK, MatsuuraE.Antigenic specificity of the ‘anticardiolipin’ antibodies.Blood1995; 85: 2277–2280.
8.
IgarashiM. Human β2-glycoprotein I as an anticardiolipin cofactor determined using deleted mutants expressed by a baculovirus system.Blood1996; 87: 3262–3270.
9.
HorkkoS. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein.J Clin Invest.1996; 98: 815–825.
10.
RoubeyRAS, EisenbergRA, HarperMF, WinfieldJB.‘Anticardiolipin’ autoantibodies recognize β2-glycoprotein I structure in the absence of phospholipid. Importance of antigen density and bivalent binding.J Immunol1995; 154: 954–960.
11.
TincaniA. The anti-β2-glycoprotein I activity in human antiphospholipid syndrome sera is due to monoreactive low-affinity autoantibodies directed to epitopes located on native β2-glycoprotein I and preserved during species’ evolution.J Immunol1996; 157: 5732–5738.
12.
SchultzeHE, HeideK, HaputH.Uber ein bisher ubekanntes niedermolekulars β2-Globulin des Humanserums.Naturwissenschaften1961; 48: 719–724.
13.
WurmH.Beta2-glycoprotein I (apolipoprotein H) interactions with phospholipid vesicles.Int J Biochem1984; 16: 511–515.
14.
PolzE.Isolation of a specific lipid-binding protein from human serum by affinity chromatography using heparin-Sepharose. In: PeetersH (ed) Protides of Biological Fluids.Pergamon Press: Oxford, pp 817.
15.
PolzE, KostnerGM.The binding of β2-glycoprotein I to human serum lipoproteins: distribution among density fractions.FEBS Lett.1979; 102: 183–186.
16.
NimpfJ. Prothrombinase activity of human platelets is inhibited by β2-glycoprotein I.Biochim Biophys Acta1986; 884: 142–149.
17.
SchousboeI.β2-glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway.Blood1985; 66: 1086–1091.
18.
NimpfJ, WurmH, KostnerGM.β2-Glycoprotein I (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation.Atherosclerosis1987; 63: 109–114.
19.
LozierJ, TakahashiN, PutnamFW.Complete amino acid sequence of human plasma β2-glycoprotein I.Proc Natl Acad Sci U.S.A.1984; 81: 3640–3644.
20.
KatoH, EnjyojiK.Amino acid sequence and location of the disulfide bonds in bovine β2-glycoprotein I: The presence of five sushi domains.Biochemistry1991; 30: 11687–11694.
21.
MatsuuraE. Molecular definition of human β2-glycoprotein I (β2-GPI) by cDNA cloning and inter-species differences of β2-GPI in alternation of anticardiolipin binding.Int Immunol1991; 3: 1217–1221.
22.
SteinkassererA. Complete nucleotide and deduced amino acid sequence of human beta2-glycoprotein I.Biochem J1991; 277: 387–391.
23.
MehdiH. Nucleotide sequence and expression of the human gene encoding apolipoprotein H (beta2-glycoprotein I).Gene1991; 108: 293–298.
24.
SteinkassererA. Activity, disulphide mapping and structural modelling of the fifth domain of human beta 2-glycoprotein I.FEBS Lett1992; 313: 193–197.
25.
HuntJE, KrilisSA.The fifth domain of β2-glycoprotein I contains a phospholipid binding site (Cys281-Cys288) and a region recognized by anticardiolipin antibodies.J Immunol1994; 152: 653–659.
26.
MatsuuraE. Molecular studies on phospholipid-binding sites and cryptic epitopes appearing on β2-glycoprotein I structure recognized by anticardiolipin antibodies.Lupus1995; 4 (Suppl 1), S13–S17.
27.
ShengY. Site-derected mutagenesis of recombinant human β2-glycoprotein I identifies a cluster of lysine residues that are critical for phospholipid binding and anti-cardiolipin antibody activity.J Immunol1996; 157: 3744–3751.
28.
HuntJE, SimpsonRJ, KrilisSA.Identification of a region of β2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity.Proc Natl Acad Sci USA1993. 90: 2141–2145.
29.
HagiharaY. Structure and function of the recombinant fifth domain of human β2-glycoprotein I: effect of specific cleavage between Lys77 and Thr78.J Biochem (Tokyo)1997; 121: 128–137.
30.
NormanDG. Three-dimensional structure of a complement control protein module in solution.J Mol Biol1991; 219: 717–725.
31.
SteinkassererA. Activity, disulphide mapping and structural modelling of the fifth domain of human beta 2-glycoprotein I.FEBS Lett1992; 313: 193–197.
32.
BrooksBR. CHARMM: a program for macromolecular energy, minimisation, and dynamics calculations.J Comput Chem1983; 4: 187–217.
33.
IchikawaK. β2-Glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome.Arthritis Rheum1994; 37: 1453–1461.
